KEGG   DRUG: D09321Help
Entry
D09321                      Drug                                   

Name
Obinutuzumab (genetical recombination (JAN);
Obinutuzumab (USAN);
Gazyva (TN)
Product
Formula
C6512H10060N1712O2020S44
Exact mass
145972.4812
Mol weight
146062.6732
Activity
Oncology, treatment of lymphoma [DS:H00005]
Remark
ATC code: 
Comment
Monoclonal antibody
Target
CD20 [HSA:931] [KO:K06466]
  Pathway
Hematopoietic cell lineage
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01X OTHER ANTINEOPLASTIC AGENTS
    L01XC Monoclonal antibodies
     L01XC15 Obinutuzumab
      D09321  Obinutuzumab (USAN)
Target-based classification of drugs [BR:br08310]
 Others
  Cellular antigens
   CD20
    Obinutuzumab
     D09321  Obinutuzumab (USAN)
Antineoplastics [br08340.html]
 D09321
New drug approvals in the USA [br08319.html]
 New Molecular Entity and New Therapeutic Biological Product Approvals
  D09321
Pharmacogenomic biomarkers in FDA drug labels [br08341.html]
 Companion diagnostics
  D09321
BRITE hierarchy
Other DBs
CAS: 
949142-50-1
PubChem: 
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system